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Abstract. Advanced-stage melanoma here dismal prognosis, and novel
therapeutic approaches are urgently required. The possibility of taking
advantage of the immune response of patients for its treatment has been
an appealing concept for almost a century. Only during the last decade,
however, has the molecular identification of tumor-associated antigens
(TAAs) offered the possibility of vaccinating patients (e.g., active induc-
tion of TAA-specific immune responses). Active antigen-specific immu-
notherapy (AASIT) is currently being investigated in a number of clinical
centers as a treatment option for advanced-stage melanoma. A large
number of melanoma TAAs have been molecularly characterized and are
being used in vaccination trials in various molecular forms and according
to various immunization protocols. Here we provide a short overview on
melanoma TAAs, the technologies currently in use to induce specific
cytotoxic T-lymphocyte (CTL) responses in vivo, and their monitoring. We
also propose a tentative AASIT agenda for the next few years, aiming at
improving the capacity to induce and monitor TAA-specific immune
responses and to verify their clinical effectiveness.
Melanoma is of peculiar fascination for tumor immunologists,
largely because of the reported occurrence of spontaneous
regressions and the association with autoimmune phenomena
(vitiligo) in cases with relatively good prognosis. Furthermore,
primary melanoma cell lines, easily generated from surgically
excised specimens, provide reagents that allow cellular immu-
nology studies in vitro using tumor cells and lymphocytes from the
same patient. A search in public literature databases yields more
than 80 entries with the keywords ‘‘melanoma and vaccinations’’,
limited to clinical trials. The frequency of these trials is clearly
increasing, albeit with partially different trends, depending on the
immunization procedure (Fig. 1).
A turning point in tumor immunology occurred in 1991 with
the description of the first human, HLA-restricted, tumor-asso-
ciated antigen (TAA) [1]. Subsequently, the identification of a
large series of TAAs [2] and the concomitant enormous increase
of knowledge in basic immunology have generated high hopes
regarding active antigen-specific immunotherapy (AASIT) of
cancer.
Here we review basic concepts underlying clinical immuno-
therapy and focus on the immunization and monitoring tech-
niques currently used in AASIT. Finally, we try to identify basic
and clinical research areas where major efforts are urgently re-
quired to strengthen the AASIT rationales and to verify its clin-
ical effectiveness.
Human Tumor-associated Antigens
The single major obstacle to application of the advances in fun-
damental immunology to cancer treatment has historically been
the absence of suitable molecularly characterized antigens. Im-
munotherapists have thus been forced to use undefined ‘‘vac-
cines’’ derived from tumor cell lines or tissues or their
corresponding lysates. Thus molecular identification of the first
human TAAs in 1991 can righteously be considered a milestone
in tumor immunology [1].
The TAAs recognized by CD8 + cytotoxic T lymphocytes
(CTLs) or CD4 + T cells were originally identified by taking
advantage of a number of methods [2]. For melanoma, they can
be classified into at least three groups (Table 1). Differentiation
antigens are typically expressed by tumor cells and by melano-
cytes, albeit at a lower level. Synthetic peptides deriving from
these proteins, frequently involved in melanogenesis, are among
the most used in the AASIT of melanoma [2–4].
Cancer/testis TAAs (C/T TAAs) are usually expressed only in
spermatogonia and in tumor cells of different histologic origin.
Their peculiar relevance is due to their relatively high tumor
specificity. Indeed, spermatogonia do not express HLA class I,
the restriction molecules for antigen recognition by CTL [1,5–
7]. ‘‘Real’’ TAAs derive from gene products resulting from
genetic alterations detectable only in tumor cells. They may
include mutations, translocations, differential splicing, or the
transcription and translation of intron sequences. Such TAAs
are important from an immunobiological viewpoint. However,
they are of limited clinical relevance in as much as their
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expression is frequently limited to tumor cells from individual
patients [8, 9]. In other tumors, but not in melanoma, antigens
derived from viruses potentially involved in the oncogenic
process represent an additional TAA group of rising impor-
tance [10].
Thus, melanoma TAAs used in clinical AASIT most frequently
derive from proteins also expressed in some type of nontumoral
cells. This implies that the immune system is likely to have
developed some degree of tolerance toward them. Recent expe-
rience suggests that this tolerance can be overcome by taking
advantage of appropriate immunization procedures. However, this
represents a major difference if one compares AASIT of cancer to
conventional preventive vaccinations targeting infectious agents.
Vaccination Protocols
Having characterized the TAAs does not automatically imply the
capacity to generate effective immune responses following vacci-
nation. Actually, all vaccines used in the prevention of infectious
diseases, with the sole exception of bacille Calmette-Gue´rin
(BCG), are effective in that they induce the generation of hu-
moral antibody responses [11]. These responses are unfit to target
human TAAs which are mostly expressed only intracellularly.
Notably, the generation of HLA class I restricted CTL responses
represents a major challenge also in preventive vaccinations
against a number of infectious diseases, such as hepatitis C [12].
In addition, the adjuvant most frequently included in com-
mercial vaccine preparations, alum, is excellent for promoting
antigen-specific antibody responses but is unable to support
CTL generation [13]. Indeed, the identification and functional
characterization of novel adjuvant formulations capable of
enhancing CTL induction represents the main research focus of
many academic centers and research and development depart-
ments of companies [14]. In this context, clinical AASTI has
played an ice-breaking role in the promoting investigations on
CTL generation.
Fig. 1. Overview of clinical trials regarding metastatic melanoma 1992–2004. The data refer to published clinical trials reported in the PUBMED public
literature database under the heading ‘‘melanoma and vaccination’’ with the ‘‘clinical trial’’ limit. Trials taking advantage of recombinant virus were
added. Note that data from individual trials were at times reported in more than one work, so the number of trials reported here is lower than the
number of entries in PUBMED. Trials taking advantage of undefined antigens (e.g., tumor cells, cellular hybrids, heat shock proteins, exosomes) are
outside the scope of this review.
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Many immunization approaches targeting molecularly defined
antigens (Table 2) have been employed in clinical trials on met-
astatic melanoma. A common starting point is that antigens rec-
ognized by CTLs, be they TAAs or viral antigens, are usually
produced inside the cells, with their peptidic fragments (epitopes)
expressed on cell surfaces inside HLA class I molecules grooves.
Thus mimicking physiologic pathways would recommend, for in-
stance, the use of virus recombinant for TAAs, capable of
infecting antigen-presenting cells (APCs). Alternatively, APCs
might be exogenously loaded with synthetic epitopes (peptides),
binding the small percentage of HLA class I molecules present on
cell surfaces in an empty state. Most immunization procedures
used for CTL generation in AASTI are based on these basic
concepts. Peptides have been injected directly, in the presence or
absence of adjuvants or supportive cytokines, or loaded ex vivo on
APCs (usually dendritic cells) prior to reinjection. Alternatively,
recombinant virus encoding TAAs in different forms have also
been used.
Soluble Peptides as Vaccines
Several groups have proposed direct administration of peptides
[34, 35], alone [15] or together with supportive cytokine treat-
ments. The latter include granulocyte/macrophage-colony-stim-
ulating factor (GM-CSF), aiming at in vivo mobilization of
endogenous (APCs), interleukins 2 or 12 (IL-2 or IL-12) to
promote the expansion of TAA-specific CTLs [16–19]. Fur-
thermore, adjuvants in experimental use, including incomplete
Freunds adjuvant [20, 21], have also been widely used. Al-
though inexpensive and easy to produce under sterile, good
manufacturing practice (GMP) conditions, peptides are fre-
quently poor immunogens largely owing to their fast hydrolysis
by serum or cell-associated peptidases [36, 37]. To circumvent
this difficulty, peptides modified to improve their resistance to
enzymatic digestion have been designed for a number of epi-
topes [38, 39].
Antigen-loaded Dendritic Cells
The wealth of information accumulated over the last years on the
immunobiology of dendritic cells (DCs), possibly the most effi-
cient APC identified so far, has readily resulted in their clinical
application in AASIT [40]. Initially, immature DCs, generated
upon culture of CD14+ peripheral blood monocytes or bone
marrow-derived CD34+ cells in the presence of IL-4 and GM-
CSF [22–24] were used.
At present, most studies take advantage of DCs matured in the
presence of cytokines because of their superior capacity to induce
CTL responses [25]. Early protocols relied on culture media that
included foreign proteins (fetal calf serum) [41], whereas nowa-
Table 1. Overview of melanoma-associated antigens.
Tumor-associated antigens in melanoma Expression pattern Immunogenicity
Selected
references
Differentiation antigens: gp100,
Melan-A/MART-1, tyrosinase,
TRP-2, among others
Tumor cells and nontransformed
melanocytes/pigmented cells:
highly frequent expression
in melanoma
Capacity to induce CTL and
CD4+ T-cell responses
2–5
Cancer/testis tumor-associated antigens:
MAGE, NY-ESO-1, among others
Spermatogonia, placenta, and tumor
cells of diﬀerent histologic
origin: expressed in 10–50% of
melanomas
Capacity to induce CTL and
CD4+ T-cell responses
1, 2, 5–7
Tumor-speciﬁc antigens derived from
mutated genes or sequences not
transcribed under physiologic conditions
Limited to tumor cells of individual
patients
Capacity to induce CTL and
CD4+ T-cell responses
8, 9
CTL: cytotoxic T lymphocyte.
Table 2. Overview of immunogens and treatment procedures most frequently used for active antigen specific immunotherapy of melanoma.
Immunogens/treatment procedures Advantages Disadvantages
Selected
references
Peptides with or without cytokines Inexpensive, easy to produce GMP Low immunogenicity, cytokine-related
side eﬀects
15–19
Peptides with adjuvants In expensive, easy to produce GMP Few licensed adjuvants capable of
inducing CTLs, side eﬀects related
to adjuvant administration
20, 21
Dendritic cells loaded with peptides Highly immunogenic Diﬃcult standardization, requirement
for preculture of patients own cells
22–27
Recombinant virus Highly immunogenic Safety concerns, expensive GMP
production, vector-speciﬁc immune
responses
28–30
Adoptive immunotherapies Possible administration of high
numbers of speciﬁc CTLs
Long-term culture of lymphocytes
required
31, 32
Adoptive immunotherapies with
pharmacological immunodepletion
Possible administration of high
numbers of speciﬁc CTLs with
prolonged survival
Side eﬀects related to immunodepletion
and autoimmunity after CTL
administration
33
GMP: good manufacturing practice
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days media containing serum autologous to the patient or serum-
free media are more frequently employed. Furthermore, both
intranodal and subcutaneous routes of administration have been
explored, at times in the presence of additional antigens capable
of eliciting strong CD4+ T-cell responses [26, 27]. The major
disadvantages of this approach are the cumbersome ex vivo cul-
ture of large numbers of monocytes or CD34+ bone marrow cells
from patients to generate DCs and the difficulty of standardizing
culture protocols [40].
Recombinant Viruses
Recombinant viruses are likely to mimick the physiological anti-
gen presentation pathways for HLA class I restricted epitopes,
thus being attractive alternatives to exogenous peptide loading.
Clinical trials taking advantage of various vectors have been
published [28–30]. In particular, our group has developed and
tested in a clinical trial a vaccinia virus-based vector including
melanoma differentiation antigens Melan-A/MART1, gp 100, and
tyrosinase genes limited to sequences encoding HLA-A0201-re-
stricted epitopes. Furthermore, genes encoding CD80 and CD86
co-stimulatory molecules were added to the vector to enhance the
generation of specific CTL [29, 30]. Recombinant viruses rank
among the most effective immunogens. However, inactivation of
the replicative capacity of the vectors, recommended to improve
the safety of these reagents may result in low expression of re-
combinant genes. In addition, vector-specific immune responses
may limit their efficacy.
Heterologous Immunization Protocols
To capitalize on the advantages of the immunization protocols
detailed above while limiting their drawbacks, ‘‘heterologous’’
procedures have also been developed [42]. Antigens are
sequentially administered in various molecular forms (e.g., as
soluble peptides and encoded within recombinant virus). Con-
sidering that TAA-specific immunization mostly requires multi-
ple boosts, these technologies are useful for reducing the extent
of vector-specific responses when recombinant viruses are also
used.
Adoptive Immunotherapies
Adoptive immunotherapies are characterized by ‘‘active’’ antigen
specific expansion of CTLs obtained in vitro. Conventional AA-
SIT has usually been applied at relatively late stages of neoplastic
diseases, such as in the presence of high numbers of tumor cells
(1 cm3 of solid tumor mass contains approximately109 neoplastic
cells). Correspondingly high numbers of specific CTLs might then
be required. Thus in addition to the difficulties inherent in CTL
generation, in common with virus-specific responses, the long-
term maintenance of large numbers of specific CTLs might be of
critical clinical relevance [43] in tumor immunotherapy. To ad-
dress this issue, adoptive immunotherapy has been used to rein-
fuse large numbers of TAA-specific CTLs generated in vitro
under controlled conditions [31, 32].
Under physiological conditions, the number of lymphocytes is
homeostatically controlled, and long-lasting major expansions of
given T-cell populations are considered possible only in lymp-
hopenic hosts [44, 45]. Capitalizing on this notion, pharmaco-
logical immunodepletion followed by adoptive transfer of
polyclonal T-cell populations recognizing TAA accompanied by
systemic recombinant IL-2 (rIL-2) treatment has been proposed
for metastatic melanoma [33]. This trial has resulted in measur-
able clinical responses in 6 of 13 patients. However, autoimmunity
inclusive of vitiligo and uveitis and high-dose IL-2-related toxicity
was observed. Furthermore, the labor-intensive culture of specific
T cells to achieve high numbers severely limits wide applicability
of this technology.
Monitoring AASIT Responses
A critical issue in AASIT is the possibility of providing direct links
between the immune responses induced and the clinical re-
sponses. This raises the problem of adequate monitoring of CTLs
induced by immunization. Again, the large body of knowledge
about preventive vaccinations is of limited use. In most cases,
their monitoring has mainly focused on the humoral response,
with titers of the antibodies specific for the targeted bacteria/
viruses the recognized gold standard. Cellular monitoring of
vaccinations against infectious diseases in humans is rare [46]. It is
Table 3. Overview of technologies currently in use for monitoring active antigen-specific immunotherapy of melanoma.
Procedure Advantages Disadvantages
Selected
references
Phenotypic assays
Tetramer staining on fresh or cultured cells Fast and highly speciﬁc; possible on
fresh blood samples
Low sensitivity; does not
provide functional information
47, 48
Functional assays
Cytotoxic activities of bulk cultures or limiting
dilution analysis of CTL precursor frequency
Provide informations about the capacity
of CTLs to kill tumor cells
Labor-intensive; requires
relatively long cultures
29, 30
Elispot, mainly, but not exclusively, for IFNc Fast and speciﬁc; requires minimal culture
times and provides functional informations
Further characterization of
speciﬁc cells diﬃcult
49
Intracellular cytokine staining of tetramer
positive cells
Fast and speciﬁc; requires minimal culture
times and provides combined phenotypic
and functional informations
Low sensitivity 50
Gene expression assays
Antigen-stimulated cytokine gene expression Fast, speciﬁc, requiring minimal culture times Requires quantitative PCR
equipment
51–53
In vivo assays
DTH In vivo antigen-speciﬁc reactivity Low sensitivity, diﬃcult
quantitation
22
IFNc: interferon-c; DTH: delayed type hypersensitivity; PCR: polymerase chain reaction.
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remarkable that the development of active AASIT has provided a
decisive impetus for the development of cellular monitoring
techniques (Table 3) as close as possible to the in vivo situation
[47].
Limiting dilution analysis (LDA) of CTL precursor frequencies
is a classic method for evaluating specific T-cell responsiveness
quantitatively. Using this technology, we were able to demon-
strate increases in TAA-specific CTLs following in vivo adminis-
tration of a recombinant vaccinia virus encoding specific epitopes
[29, 30]. However, the detection of CD8+ effector cells in LDA,
usually performed using cytotoxicity assays, requires their
expansion in >10-day cultures typically supplemented with
exogenous cytokines. This raises the question of the in vivo rel-
evance of the data obtained.
Tetramers are multivalent fluorochrome-labeled reagents con-
sisting of entire HLA class I dimers in soluble form containing
specific antigenic peptides in their binding grooves. Therefore
tetramer staining allows fluorescence labeling of T cells express-
ing antigen receptors specific for defined peptides in the context
of defined HLA restrictions. The development of tetramers [48]
has represented a revolution in CTL monitoring in both basic
immunology and clinical trials [47]. Importantly, these tetramers
can be used on fresh uncultured cells. The main pitfalls concern
the sensitivity of this technology, allowing reliable detection by
flow cytometry of frequencies of CTLs in the 1: 2000 to 1/10,000
range. This is often insufficient for direct ex vivo evaluation.
Furthermore, this technology, a current standard, falls short of
providing functional data about antigen-specific T cells. To cir-
cumvent this difficulty, the intracellular staining of tetramer-po-
sitive cells with cytokine-specific monoclonal antibodies following
short incubations (4–6 hours) in the presence of specific antigens
has been proposed [50].
Elispot technology also represents a standard in tumor vac-
cination protocols. It is based on the notion that upon
encountering the specific antigen activated T cells produce
cytokines. Their detection as ‘‘spots’’ on the bottom of culture
plates by immunoenzymatic methods allows accurate, sensitive
quantification of the number of T cells responding to a given
TAA. The culture time required usually does not exceed 24
hours. A drawback is that it is impossible to study ‘‘positive
cells’’ further for additional functional and phenotypic charac-
terization [49].
More recently, monitoring techniques based on the detection of
cytokine gene expression following short-term exposure of T cells
to antigens by quantitative reverse transcription-polymerase chain
reaction TaqMan technologies have also been developed [51, 52].
A main question in the monitoring of AASIT regards the
nature of the cells to be monitored. Usually, accessible T cells are
from peripheral blood. However, because activated cells are
known to extravasate, some groups advocate monitoring satellite
lymph nodes or tumor tissues, with the material collected by fine-
needle aspiration [53].
Toxicity
Most of the AASIT protocols described above have been shown
to be devoid of significant toxicity, as indicated by their safe
application in relatively large numbers of patients. Most fre-
quently detected side effects range from autoimmunity of varying
extent to effects attributable to the supporting cytokines or ad-
juvants or specific vaccine formulations. They range from skin
rash and flu-like symptoms to life-threatening leak syndromes.
In melanoma AASIT, vitiligo, which results from targeting of
melanocytes by CTLs specific for differentiation antigens [54], is
usually localized and frequently considered a favorable prognostic
marker. Other pigmented tissues, however, including the retina
and substantia nigra, might also be recognized by these T cells. It
could be speculated that the usual absence of ocular or neurologic
symptoms in patients vaccinated with melanoma differentiation
antigens may be related to poor immunization rather than to
immune privileges of defined anatomic districts.
Indeed, it has been shown that functional blockade of CTLA-4,
an antagonist of T-cell activation, may result in severe autoim-
munity, affecting multiple organs [55]. Clearly, improvements in
the effectiveness of vaccination strategies call for careful investi-
gations regarding the fine line between therapeutic efficacy and
undesired autoimmunity.
Adjuvants may also cause severe toxic side effects [56].
Regarding cytokines, IL-2 and IL-12 toxicities have widely been
reported [57, 58]. Furthermore, GM-CSF, which is frequently
used as a supportive cytokine during vaccination protocols, has
been shown to cause somewhat milder side effects, including skin
rashes [59, 60].
Clinical Effects
Despite years of clinical investigations with a wealth of clinical
trials, we are still unable to provide solid data regarding the
clinical effectiveness of AASIT in melanoma. Indeed, spontane-
ous regression of melanomas have been reported in the past [61,
62]. Evidence of tumor regression of varying extent has ranged
between 10% and > 40% of the patients enrolled in clinical
AASIT trials (Table 2). Can this be attributed merely to spon-
taneous tumor regression? On the other hand small-scale non-
randomized clinical trials are frequently subject to subtle bias
during the patients recruitment, the impact of which is difficult to
quantify. Thus evidence of clinical effects still must to be con-
sidered anecdotal in the absence of randomized control groups or
Phase III adjuvant studies in high risk patients [63]. Clearly,
organizational and financial problems play a major role. Other
issues, however, should also be considered. First, there is no
standard treatment for metastatic melanoma against which to
compare the outcome of immunization procedures. Interferon
(IFN) type I is widely used. However, IFN administration pro-
tocols largely differ in timing and dosage; and considering its
inherent toxicity, many oncologists choose not to use it.
Immunization and monitoring protocols show wide variations
and are difficult to standardize. The numbers of patients required
to provide statistically significant results are high and require the
development of multicenter trials. Also, the unwillingness of pa-
tients bearing advanced tumors to participate to randomized
studies should not be underestimated.
Although formal proof of the clinical effectiveness of AASIT is
missing, preliminary explanations of its failures can now be pro-
posed. As detailed above, not only CTL generation remains a
challenge, but the mere ‘‘self’’ nature of most TAAs provides
additional hurdles because of existing tolerance. Furthermore,
current trials mostly recruit patients in advanced stages of the
disease who are possibly immunodepressed. Large tumor burdens
are unlikely targets of CTLs because of the unfavorable ratio
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between the numbers of specific T cells and tumor cells. Last, but
perhaps most importantly, tumor cells have been shown to have
developed a number of strategies to escape recognition by the
immune system. Such mechanisms range from down-regulation of
TAA or HLA molecule expression to actively killing CTLs [64].
Outlook
Where should we go from here? In our opinion, the main
advantage of AASIT compared to other immunotherapy strate-
gies may rely on the possibility of establishing a solid relation
between immune responses to molecularly defined antigens and
clinical responsiveness. Currently, this is still a major unfulfilled
goal of our translational research.
Admittedly, the TAAs identified so far do not represent ideal
targets inasmuch as they are not uniquely tumor-specific. Fur-
thermore, because their expression is not linked with oncogenesis
or tumor cell survival, they are dispensable for cancer growth.
Therefore, despite the large number of TAAs described so far,
there is still wide room for research in this area.
A clinical AASIT agenda urgently requires the performance of
rigorously controlled randomized trials and Phase III adjuvant
studies for high risk melanoma. Such investigations, by definition,
imply the engagement of a number of clinical centers and con-
siderable financial efforts. Notably, the funds necessary are usu-
ally too high for academic institutions or public research agencies,
and the interest of pharmaceutical companies in this area is still
limited.
Most importantly, however, performing multicenter trials
mandates the choice of easily standardizable immunogens and
immunization techniques. Monitoring technologies should also be
refined and standardized, possibly avoiding in vitro culture steps
without jeopardizing their sensitivity. Patients with a high risk of
recurrence or who have been surgically rendered tumor-free
should be specifically considered.
On the other hand, the data obtained so far underline, at best,
the incomplete nature of our understanding of the rules govern-
ing the generation and maintenance of CTL immune responses
and urge renewed basic research efforts.
Indeed, the best investigated experimental models of CTL re-
sponse to viral challenges provide arguments for reflection. The
kinetics of CTL responses in these studies are classically charac-
terized by a CTL expansion phase upon infection or vaccination,
followed within weeks by a contraction phase [65] with the per-
sistence of low numbers of memory cells, characterized by a slow
renewal.
Consistent with these investigations, the few published AASIT
clinical trials reporting the kinetics of immune responses even-
tually induced [25, 29, 30, 39] indicate that responsiveness is
mostly short-lived and rarely sustained. These ephemeral re-
sponses might be capable of facing viral infections and might
result in clearance of the aggressor. However, tumor-specific
therapeutic vaccination shares the same tools as virus-specific
immune responses (e.g., class I restricted CTLs) but presents
peculiar features. In the presence of substantial tumor burdens,
clearance of neoplastic cells might be an unlikely outcome even
following successful immunization. Developing clinically applica-
ble protocols that allow maintenance of large numbers of specific
memory CTLs is an important challenge for tumor immunolo-
gists.
Conclusions
Immunotherapy is slowly finding its place into antitumor weap-
onry. In a field typically characterized by waves of enthusiasm and
disappointment, we are presently witnessing an unusual reflective
phase. Past the era of molecularly undefined reagents, we are now
able to use the science of immunology for the good of our
patients. The complexity of this science could justifiably lead to
skepticism [66]. However, the continuous refinements to the art of
induction and maintenance of cellular immune responses might
provide a reasoned, low-key optimism for the future.
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